At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Ixazomib 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Phase II Study of Ixazomib for the Prevention of Recurrent or Late Acute and Chronic Graft-versus-Host Disease at 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating Ixazomib for Myeloid Hematologic Malignancy and Lymphoid Hematologic Malignancy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI) or non-myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMillennium: The Takeda Oncology Company
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionSep 2021
TodayJul 2026
First PostedMar 17, 2017
Enrollment StartMar 10, 2017
Primary CompletionSep 2, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.3 years ago
Interventions
Ixazomibdrug
Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).